Higher Levels of Surface CD20 Expression on Circulating Lymphocytes Compared With Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic Leukemia
| Autor: | Iman Jilani, Susan Lerner, Michael J. Keating, Yang O. Huh, Maher Albitar, Helene L. Saffer |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Pathology medicine.medical_specialty Chronic lymphocytic leukemia Follicular lymphoma Antineoplastic Agents Lymphoma Mantle-Cell Antibodies Monoclonal Murine-Derived Bone Marrow immune system diseases hemic and lymphatic diseases medicine Humans Hairy cell leukemia Lymphoma Follicular CD20 B-Lymphocytes biology business.industry Splenic Neoplasms Antibodies Monoclonal General Medicine Antigens CD20 Flow Cytometry medicine.disease Leukemia Lymphocytic Chronic B-Cell Lymphoma Leukemia biology.protein Mantle cell lymphoma Lymph Nodes Rituximab business Splenic Lymphoma |
| Zdroj: | American Journal of Clinical Pathology. 116:437-443 |
| ISSN: | 1943-7722 0002-9173 |
| Popis: | Differential expression of CD20 surface antigen in B-cell neoplasms at different sites is largely unknown. The number of CD20 antibodies bound per cell (CD20 ABC) in bone marrow (BM), peripheral blood (PB), and lymph node aspirate (LNA) samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) or other B-cell disease was studied using quantitative flow cytometry. CD20 ABC differed significantly with the specimen type in B-CLL, being highest in PB (mean, 9,051) and lower in BM (mean, 4,067) and LNA (mean, 3,951). No difference in CD20 ABC between BM and PB samples was found in splenic lymphoma, mantle cell lymphoma, or follicular lymphoma. Also, we found a significant difference of CD20 ABC by type of disease: lowest in B-CLL; higher in splenic, follicular, and mantle cell lymphoma; and highest in hairy cell leukemia. The lower CD20 surface antigen levels in BM and LNA than in PB in B-CLL may have clinical relevance with regard to the efficacy of rituximab therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|